NCT06809400

A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 127 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 30 Years – 85 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson's disease.

Detailed description

The screening period will be up to 120 days for participants with Parkinson's disease who receive 4 doses, and up to 35 days for healthy participants who receive 1 dose. The treatment and follow-up duration will be up to 61 weeks for participants with Parkinson's disease, and 48 weeks for healthy participants. The total study duration will be up to 78 weeks for participants with Parkinson's disease, and 53 weeks for healthy participants.

Conditions

• Parkinson Disease

Interventions

Type	Name	Description
DRUG	LY4006896	Administered intravenously (IV)
DRUG	Placebo	Administered IV

Timeline

• Start date: 2025-02-18
• Primary completion: 2028-01-01
• Completion: 2028-01-01
• First posted: 2025-02-05
• Last updated: 2026-03-20

Locations

14 sites across 2 countries: United States, Japan

Regulatory

• FDA-regulated drug study